S-K 1603(a)(9) Restrictions on Selling Securities |
Sep. 15, 2025 |
|---|---|
| Founder Shares [Member] | |
| SPAC Sponsor and Affiliates Information, Restrictions on Sale of SPAC Securities [Line Items] | |
| SPAC Sponsor, Description of Expiration Dates of Restrictions [Text Block] | (i) with respect to 50% of the founder shares, the earlier of six months after the date of the consummation of our initial business combination and the date on which the closing price of our ordinary shares equals or exceeds $12.50 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after our initial business combination and (ii) with respect to the remaining 50% of the founder shares, six months after the date of the consummation of our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. |
| SPAC Sponsor, Persons and Entities Subject to Restrictions | Drugs Made In America Acquisition II LLC, Lynn Stockwell, Glenn Worman, Catherine Do, G. Sridhar Prasad and Myron W. Shulgan |
| SPAC Sponsor, Description of Exceptions to Restrictions [Text Block] | Pursuant to a letter agreement with us, our initial shareholders have agreed not to transfer, assign or sell any of their founder shares or the private units, including the underlying private shares and private rights, until the earlier to occur of: (i) with respect to 50% of the founder shares and private units, the earlier of six months after the date of the consummation of our initial business combination and the date on which the closing price of our ordinary shares equals or exceeds $12.50 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after our initial business combination and (ii) with respect to the remaining 50% of the founder shares and private units, six months after the date of the consummation of our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property (except with respect to permitted transferees as described herein under “Principal Shareholders — Restrictions on Transfers of Founder Shares and Private Units”). However, if after a business combination there is a transaction whereby all the outstanding shares are exchanged or redeemed for cash (as would be the case in a post-asset sale liquidation) or another issuer’s shares then the founder shares and the private units (or any ordinary shares underlying thereunder) shall be permitted to participate. We refer to such transfer restrictions throughout this prospectus as the lock-up. We could agree to permit the holders of our founder shares to transfer shares or agree to cancel such securities. Although no such transfers or cancellations are contemplated, we could agree to permit such transfer or cancellation to facilitate the closing of a business combination. Any permitted transferees would be subject to the same restrictions and other agreements of our initial shareholders with respect to any founder shares. |
| Private Units [Member] | |
| SPAC Sponsor and Affiliates Information, Restrictions on Sale of SPAC Securities [Line Items] | |
| SPAC Sponsor, Description of Expiration Dates of Restrictions [Text Block] | 30 (i) with respect to 50% of the private units, including the underlying private shares and private rights, the earlier of six months after the date of the consummation of our initial business combination and the date on which the closing price of our ordinary shares equals or exceeds $12.50 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after our initial business combination and (ii) with respect to the remaining 50% of the private units, including the underlying private shares and private rights, six months after the date of the consummation of our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. |
| SPAC Sponsor, Persons and Entities Subject to Restrictions | Drugs Made In America Acquisition II LLC and Lynn Stockwell |
| SPAC Sponsor, Description of Exceptions to Restrictions [Text Block] | Same as for the founder shares |